Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial

Gastroenterology

Volumn 125, Issue 2, 2003, Pages 328-336

  Benamouzig, Robert ^a   Deyra, Jacques ^b   Martin, Antoine ^a   Girard, Bernard ^c   Jullian, Eric ^b   Piednoir, Benoit ^c   Couturier, Daniel ^b   Coste, Thierry ^a   Little, Julian ^d   Chaussade, Stanislas ^b  

^a AVICENNE HOSPITAL   (France)

^b Cochin Hospital ^*  (France)

^c University Paris I Sorbonne Panthéon   (France)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LYSINE ACETYLSALICYLATE; PLACEBO;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; COLON ADENOMA; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM ADENOMA; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0042031492     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00887-4     Document Type: Article

References (47)

1. IARC Working Group on the Evaluation of Cancer Preventive Agents. Non-steroidal anti-inflammatory drugs. Lyon, International Agency for Research on Cancer. Lyon, France: World Health Organization, 1997.
2. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996;14:551-553.
3. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli A. Aspirin and colorectal cancer. Br J Cancer 1997;76:675-677.
4. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:2326-2333.
5. Neugut Al, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998;7:869-873.
6. Bucher C, Jordan P, Nickeleit V, Torhorst J, Mihatsch MJ. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin. Clin Nephrol 1999;51:67-72.
7. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999;159:161-166.
8. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-68.
9. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-1646.
10. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000;11:249-255.
11. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1998;48:4399-4404.
12. Giovanucci E, Rimm EB, Stamfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer adenoma in male health professionals. Ann Intern Med 1994;121:241-246.
13. Giovanucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-614.
14. Muller AD, Sonnenberg A, Wasseman IH. Diseases preceding colon cancer. A case control study among veterans. Dig Dis Sci 1994;39:2480-2484.
15. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-399.
16. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88:1652-1656.
17. Wishingrad M, Titzer D, Triadafopoulos G, Omary B. Chronic aspirin and NSAID use may protect against colorectal adenomas (abstr). Gastroenterology 1994;112:A452.
18. Macrae FA, Russell A, MacLennan R. Aspirin effects on large adenomas (abstr). Gastroenterology 1994;112:A413.
19. Tosteson T, Greenberg E, Baron J. Aspirin use and reduced occurrence of large bowel adenomas (abstr). Gastroenterology 1995;108:A39.
20. Johanson JF, Salisbury D. Effectiveness of aspirin in preventing colorectal adenomas: does dose matter (abstr)? Gastroenterology 1995;114:A606.
21. Kahn HS, Tatham LM, Thun MJ, Heath CW. Risk factors for self-reported colon polyps. J Gen Intern Med 1998;13:303-310.
22. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998;114:441-447.
23. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000;11:376-381.
24. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, Goebell H. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 2000;61:129-134.
25. Benamouzig R. Do aspirin or nonsteroidal anti-inflammatory drugs decrease the risk of colorectal cancer? Gastroenterol Clin Biol 1998;22:S22-S27.
26. Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Steele VE, Hawk EE, Kelloff GJ, Pereira MA. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999;20:425-430.
27. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin use and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1120-1124.
28. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998;128:713-720.
29. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
30. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg R, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil FU, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899.
31. Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut 1998;43:578-585.
32. Raschka C, Koch HJ. Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicicylic acid in healthy volunteers. Therapie 2001;56:669-674.
33. Benamouzig R, Yoon H, Little J, Martin A, Couturier D, Deyra J, Coste T, Chaussade S. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. Eur J Cancer Prev 2001;10:327-335.
34. Yoon H, Martin A, Benamouzig R, Longchampt E, Deyra J, Chaussade S, Pour le groupe d'etude APACC. Inter-observer agreement on histological diagnosis of colorectal polyps: the APACC study. Gastroenterol Clin Biol 2002;26:220-224.
35. Winawer SJ, Zauber AG, Ho AN, O'Brien MJ, Gottlieb LS, Stenberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Acrkroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, the National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329:1977-1981.
36. Baron JA, Beach M, Mandel JS, Van Stolk RU, Haile RW, Sandler RS, Rothstein R, Summers RW, Snover DC, Beck GJ, Bond JH, Greenberg ER. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-107.
37. Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology 2001;120:1077-1083.
38. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
39. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 1990;82:1769-1772.
40. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-28.
41. Bensen S, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. Am J Gastroenterol 1999;94:194-199.
42. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, Weissfeld J, Burt R, Cooper MR, Kikendall JW, Cahill J. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149-1155.
43. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Atttali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.
44. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641-645.
45. Gupta RA, DuBois RN. Aspirin, NSAIDs, and colon cancer prevention: mechanisms? Gastroenterology 1998;114:1095-1098.
46. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002;42:55-80.
47. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-13931.